title: Follow-up of infants given measles vaccine at 6 months of age: antibody and CMI responses to MMRII at 15 months of age and antibody levels at 27 months of age.
abstract: The worldwide elimination of measles is an important target. In developed countries, to control measles outbreaks, immunization from 6 months of age is recommended. In this study, infants (n = 290) who were (1) born to mothers with natural immunity or to vaccinated mothers and (2) previously immunized with Connaught (CLL) or AIK-C measles vaccine at 6 months of age, were evaluated for measles immunity before and after measles-mumps-rubella (MMRII at 15 months of age. Eight weeks after MMRII, 98.9% of infants were seropositive by enzyme immunoassay (EIA) and 70% demonstrated measles specific cellular immunity by blast transformation (BT) of lymphocytes. At 27 months of age, 98.4% of infants had protective antibody levels by plaque reduction neutralization (PRN) test. These results suggest that AIK-C and CLL vaccines elicit durable protective immunity in young infants when used in early immunization programs.
authors.affiliation: Department of Pediatrics, University of Alberta, Edmonton, Canada. mcarson@cha.ab.ca
authors.forename: Mary M
authors.initials: MM
authors.lastname: Carson
authors.forename: Donald W
authors.initials: DW
authors.lastname: Spady
authors.forename: Judith A
authors.initials: JA
authors.lastname: Beeler
authors.forename: Margaret P
authors.initials: MP
authors.lastname: Krezolek
authors.forename: Susette
authors.initials: S
authors.lastname: Audet
authors.forename: Henry F
authors.initials: HF
authors.lastname: Pabst
mesh_terms: D000375:Aging / Q000276:immunology; D000914:Antibodies, Viral / Q000032:analysis / Q000096:biosynthesis*; D002675:Child, Preschool; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007111:Immunity, Cellular / Q000276:immunology; D007115:Immunization Schedule; D007124:Immunoenzyme Techniques; D007223:Infant; D008213:Lymphocyte Activation; D008297:Male; D008458:Measles Vaccine / Q000009:adverse effects / Q000276:immunology*; D022542:Measles-Mumps-Rubella Vaccine / Q000009:adverse effects / Q000276:immunology*; D009500:Neutralization Tests
chemical_list: D000914:Antibodies, Viral; D008458:Measles Vaccine; D022542:Measles-Mumps-Rubella Vaccine